Canada· CA-DIN-02423596
INCRUSE ELLIPTA
A umeclidinium bromide product containing umeclidinium (umeclidinium bromide), registered in Canada by GLAXOSMITHKLINE INC. The same ATC class is registered in 12 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Umeclidinium bromide is registered in 12 of 19 countries.
Countries holding a registration under ATC R03BB07 (umeclidinium bromide), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Umeclidinium bromide · ATC R03BB07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of umeclidinium bromide costs, country by country.
Normalised to the WHO defined daily dose (55 mcg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Umeclidinium bromide · price per daily dose (55 mcg)
USD · FX 28 Sept 2026
- CH Switzerland$1.57
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- UMECLIDINIUM (UMECLIDINIUM BROMIDE)
- Manufacturer
- GLAXOSMITHKLINE INC
- Country
- Canada (CA)
- ATC code
- R03BB07
- ATC class
- Umeclidinium bromide
- Defined daily dose
- 55 mcg, Inhal
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
114 interactions on record for umeclidinium bromide.
Graded by severity as the source publishes them — 113 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Umeclidinium bromide · interactions on record
114 records
- 113 moderate
- 1 minor
Most severe, free to view
- DicycloverineA03AA07moderate
- PropanthelineA03AB05moderate
- MepenzolateA03AB12moderate
- TrospiumA03AB20moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Umeclidinium bromide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIncruse Ellipta 55micrograms/dose dry powder inhalerCST Pharma Ltd
- CzechiaINCRUSE ELLIPTAGlaxoSmithKline Trading Services Limited, Dublin
- BelgiumElebrato Ellipta 92 µg/dose - 22 µg/doseGlaxoSmithKline Trading Services
- SpainINCRUSE ELLIPTA 55 mcg POLVO PARA INHALACION UNIDOSISGlaxosmithkline Trading Services Limited
- FinlandIncruse ElliptaGlaxoSmithKline Trading Services Limited
- NetherlandsIncruse Ellipta 55 microgram inhalatiepoeder, voorverdeeldGlaxoSmithKline Trading Services Limited
- PolandIncruse ElliptaGlaxoSmithKline (Ireland) Limited
- SwedenIncruse Ellipta 55 mikrogram Inhalationspulver, avdelad dosGlaxoSmithKline Trading Services Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Incruse Ellipta, Rolufta Ellipta
- Liechtenstein · Incruse Ellipta, Rolufta Ellipta
- Norway · Incruse Ellipta, Rolufta Ellipta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4218b2ec-0697-45de-8af3-fece22b6ed8c GET /v1/drugs/4218b2ec-0697-45de-8af3-fece22b6ed8c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02423596",
"form": "POWDER",
"class": "Human",
"routes": [
"INHALATION"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "R03BB07",
"schedule": [
"Prescription"
],
"drug_code": "90830",
"strengths": [
"62.5 MCG"
],
"ahfs_class": null,
"substances": [
"UMECLIDINIUM (UMECLIDINIUM BROMIDE)"
],
"product_categorization": null
}See everything about umeclidinium bromide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.